Johannes Oldenburg

Director of the Institute of Experimental Haematology and Transfusion Medicine
University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany

Presentation(s):

• OC 30.5 - Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

  Monday, July 11, 2022
  11:45 AM – 12:00 PM

• PB0671 - Analysis of F8 Genotypes and Pharmacodynamic and Safety Biomarkers in People with Moderate or Mild Hemophilia A Receiving Emicizumab in the HAVEN 6 Trial

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 63.3 - Safety and Efficacy of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Hemophilia B

  Tuesday, July 12, 2022
  3:15 PM – 3:30 PM

• OC 70.2 - Safety of Intramuscular COVID-19 Vaccination in Patients With Hemophilia

  Wednesday, July 13, 2022
  10:30 AM – 10:45 AM